Stay updated on Fruquintinib & Tislelizumab in Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the Fruquintinib & Tislelizumab in Solid Tumors Clinical Trial page.

Latest updates to the Fruquintinib & Tislelizumab in Solid Tumors Clinical Trial page
- Check7 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check15 days agoChange DetectedThe web page has been updated to announce the modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference2%
- Check22 days agoChange DetectedThe page now indicates that results have been submitted, replacing the previous message that no results were posted.SummaryDifference0.1%
- Check43 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check58 days agoChange DetectedThe web page has undergone significant changes, including the removal of detailed study descriptions and inclusion/exclusion criteria for a clinical trial, while retaining the study's collaborators and revision information.SummaryDifference19%
- Check65 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and the date has changed from March 25, 2025, to March 20, 2025.SummaryDifference0.3%
Stay in the know with updates to Fruquintinib & Tislelizumab in Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Fruquintinib & Tislelizumab in Solid Tumors Clinical Trial page.